Cambridge Healthtech Institute第5屆

Adoptive T Cell Therapy 2: Development

( 過繼T細胞免疫療法2:開發 )

2018年8月30日~31日


本單元以過繼T細胞療法藥物的開發為主題,聚焦於利用嵌合抗原受體(CAR)、T細胞受體(TCR)、腫瘤內浸潤淋巴球(TIL)的療法實用化方面之必要步驟。臨床研究的進展、個案研究、在使過繼T細胞療法能有效發揮功能上具備重要意義的要素等議題也將被包含在內。

Coverage will include, but is not limited to:

  • What's New in Adoptive Cell Therapy
    • New developments: Leapfrogging to commercialization
    • New tools: Next-gen CAR designs, gene editing, off-the-shelf cells
    • Emerging targets: Tumor-specific mutations
  • Autologous Immune Cell Products
  • Adoptive Cell Therapy Using Non-Genetically Manipulated Lymphocytes
    • Improving and extending T cell therapies to target tumor-specific mutation
  • Adoptive Cell Therapy Using Chimeric Antigen Receptors (CAR) and T Cell Receptors (TCR)
    • Increasing T cell potency and persistence
    • Creating more controllable T cells
    • Moving towards treatment of solid malignancies
    • Clinical trial updates
  • Allogeneic Immune Cell Products
    • New platform technologies
    • Preclinical data and clinical studies

* 活動內容有可能不事先告知作更動及調整。

Choose your language
Chinese
Japanese
Korean
English





免費電子郵件通知服務